- Home
- LAB vs BCYC Comparison
LAB vs BCYC Comparison
Compare LAB & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAB
- BCYC
- Stock Information
- Founded
- LAB 1999
- BCYC 2009
- Country
- LAB United States
- BCYC United Kingdom
- Employees
- LAB 818
- BCYC N/A
- Industry
- LAB Biotechnology: Laboratory Analytical Instruments
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- LAB Industrials
- BCYC Health Care
- Exchange
- LAB Nasdaq
- BCYC Nasdaq
- Market Cap
- LAB 504.2M
- BCYC 492.1M
- IPO Year
- LAB 2011
- BCYC 2019
- Fundamental
- Price
- LAB $1.30
- BCYC $7.96
- Analyst Decision
- LAB Buy
- BCYC Buy
- Analyst Count
- LAB 2
- BCYC 11
- Target Price
- LAB $2.50
- BCYC $22.91
- AVG Volume (30 Days)
- LAB 1.2M
- BCYC 303.4K
- Earning Date
- LAB 10-29-2025
- BCYC 10-30-2025
- Dividend Yield
- LAB N/A
- BCYC N/A
- EPS Growth
- LAB N/A
- BCYC N/A
- EPS
- LAB N/A
- BCYC N/A
- Revenue
- LAB $172,271,000.00
- BCYC $19,281,000.00
- Revenue This Year
- LAB N/A
- BCYC N/A
- Revenue Next Year
- LAB N/A
- BCYC N/A
- P/E Ratio
- LAB N/A
- BCYC N/A
- Revenue Growth
- LAB 76.33
- BCYC N/A
- 52 Week Low
- LAB $0.92
- BCYC $6.10
- 52 Week High
- LAB $2.32
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- LAB 48.53
- BCYC 58.20
- Support Level
- LAB $1.25
- BCYC $7.40
- Resistance Level
- LAB $1.38
- BCYC $8.69
- Average True Range (ATR)
- LAB 0.07
- BCYC 0.38
- MACD
- LAB -0.00
- BCYC 0.11
- Stochastic Oscillator
- LAB 26.83
- BCYC 62.23
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.